Rapid achievement of low disease activity during the use of a type I interferon inhibitor in a patient with torpid systemic lupus erythematosus (case report)
This article describes the experience of using the type I interferon inhibitor anifrolumab (AFM) in a patient with a torpid course of systemic lupus erythematosus. The reason for prescribing AFM was the need for a quick achievement of low disease activity due to a planned hip replacement. Dynamic ob...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2024-06-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/1591 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849242091240030208 |
|---|---|
| author | A. A. Baranov E. A. Aseeva S. K. Soloviev N. Yu. Nikishina E. A. Malygina T. O. Abissova Z. Yu. Pimenova T. M. Reshetnyak S. A. Makarov N. A. Lapkina A. M. Lila |
| author_facet | A. A. Baranov E. A. Aseeva S. K. Soloviev N. Yu. Nikishina E. A. Malygina T. O. Abissova Z. Yu. Pimenova T. M. Reshetnyak S. A. Makarov N. A. Lapkina A. M. Lila |
| author_sort | A. A. Baranov |
| collection | DOAJ |
| description | This article describes the experience of using the type I interferon inhibitor anifrolumab (AFM) in a patient with a torpid course of systemic lupus erythematosus. The reason for prescribing AFM was the need for a quick achievement of low disease activity due to a planned hip replacement. Dynamic observational data over a six-month period confirmed that AFM enables a rapid achievement of low disease activity without increasing the dose of glucocorticoids, significantly improve the patient's quality of life and even prepare them for major surgery without exacerbating the underlying process. |
| format | Article |
| id | doaj-art-d7939f7d364b40d28150d2b59f8fe2fb |
| institution | Kabale University |
| issn | 1996-7012 2310-158X |
| language | Russian |
| publishDate | 2024-06-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Современная ревматология |
| spelling | doaj-art-d7939f7d364b40d28150d2b59f8fe2fb2025-08-20T03:59:56ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2024-06-01183717710.14412/1996-7012-2024-3-71-772687Rapid achievement of low disease activity during the use of a type I interferon inhibitor in a patient with torpid systemic lupus erythematosus (case report)A. A. Baranov0E. A. Aseeva1S. K. Soloviev2N. Yu. Nikishina3E. A. Malygina4T. O. Abissova5Z. Yu. Pimenova6T. M. Reshetnyak7S. A. Makarov8N. A. Lapkina9A. M. Lila10Yaroslavl State Medical University, Ministry of Health of RussiaV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyYaroslavl Regional Clinical HospitalYaroslavl Regional Clinical HospitalYaroslavl Regional Clinical HospitalV.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuing Professional Education, Ministry of Health of RussiaV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuing Professional Education, Ministry of Health of RussiaThis article describes the experience of using the type I interferon inhibitor anifrolumab (AFM) in a patient with a torpid course of systemic lupus erythematosus. The reason for prescribing AFM was the need for a quick achievement of low disease activity due to a planned hip replacement. Dynamic observational data over a six-month period confirmed that AFM enables a rapid achievement of low disease activity without increasing the dose of glucocorticoids, significantly improve the patient's quality of life and even prepare them for major surgery without exacerbating the underlying process.https://mrj.ima-press.net/mrj/article/view/1591systemic lupus erythematosusinterferon receptorsinterferon αanifrolumab |
| spellingShingle | A. A. Baranov E. A. Aseeva S. K. Soloviev N. Yu. Nikishina E. A. Malygina T. O. Abissova Z. Yu. Pimenova T. M. Reshetnyak S. A. Makarov N. A. Lapkina A. M. Lila Rapid achievement of low disease activity during the use of a type I interferon inhibitor in a patient with torpid systemic lupus erythematosus (case report) Современная ревматология systemic lupus erythematosus interferon receptors interferon α anifrolumab |
| title | Rapid achievement of low disease activity during the use of a type I interferon inhibitor in a patient with torpid systemic lupus erythematosus (case report) |
| title_full | Rapid achievement of low disease activity during the use of a type I interferon inhibitor in a patient with torpid systemic lupus erythematosus (case report) |
| title_fullStr | Rapid achievement of low disease activity during the use of a type I interferon inhibitor in a patient with torpid systemic lupus erythematosus (case report) |
| title_full_unstemmed | Rapid achievement of low disease activity during the use of a type I interferon inhibitor in a patient with torpid systemic lupus erythematosus (case report) |
| title_short | Rapid achievement of low disease activity during the use of a type I interferon inhibitor in a patient with torpid systemic lupus erythematosus (case report) |
| title_sort | rapid achievement of low disease activity during the use of a type i interferon inhibitor in a patient with torpid systemic lupus erythematosus case report |
| topic | systemic lupus erythematosus interferon receptors interferon α anifrolumab |
| url | https://mrj.ima-press.net/mrj/article/view/1591 |
| work_keys_str_mv | AT aabaranov rapidachievementoflowdiseaseactivityduringtheuseofatypeiinterferoninhibitorinapatientwithtorpidsystemiclupuserythematosuscasereport AT eaaseeva rapidachievementoflowdiseaseactivityduringtheuseofatypeiinterferoninhibitorinapatientwithtorpidsystemiclupuserythematosuscasereport AT sksoloviev rapidachievementoflowdiseaseactivityduringtheuseofatypeiinterferoninhibitorinapatientwithtorpidsystemiclupuserythematosuscasereport AT nyunikishina rapidachievementoflowdiseaseactivityduringtheuseofatypeiinterferoninhibitorinapatientwithtorpidsystemiclupuserythematosuscasereport AT eamalygina rapidachievementoflowdiseaseactivityduringtheuseofatypeiinterferoninhibitorinapatientwithtorpidsystemiclupuserythematosuscasereport AT toabissova rapidachievementoflowdiseaseactivityduringtheuseofatypeiinterferoninhibitorinapatientwithtorpidsystemiclupuserythematosuscasereport AT zyupimenova rapidachievementoflowdiseaseactivityduringtheuseofatypeiinterferoninhibitorinapatientwithtorpidsystemiclupuserythematosuscasereport AT tmreshetnyak rapidachievementoflowdiseaseactivityduringtheuseofatypeiinterferoninhibitorinapatientwithtorpidsystemiclupuserythematosuscasereport AT samakarov rapidachievementoflowdiseaseactivityduringtheuseofatypeiinterferoninhibitorinapatientwithtorpidsystemiclupuserythematosuscasereport AT nalapkina rapidachievementoflowdiseaseactivityduringtheuseofatypeiinterferoninhibitorinapatientwithtorpidsystemiclupuserythematosuscasereport AT amlila rapidachievementoflowdiseaseactivityduringtheuseofatypeiinterferoninhibitorinapatientwithtorpidsystemiclupuserythematosuscasereport |